Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance

Arch Intern Med. 2001 Apr 9;161(7):1012-3. doi: 10.1001/archinte.161.7.1012.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aryl Hydrocarbon Hydroxylases*
  • Biological Availability
  • Cyclosporine / metabolism
  • Cyclosporine / pharmacokinetics
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Cytochrome P-450 Enzyme System / metabolism
  • Drug Interactions
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / metabolism*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics*
  • Mixed Function Oxygenases / antagonists & inhibitors
  • Mixed Function Oxygenases / metabolism
  • Practice Guidelines as Topic
  • Pravastatin / metabolism
  • Pravastatin / pharmacokinetics
  • Pyridines / metabolism
  • Pyridines / pharmacology
  • Safety*
  • Steroid 16-alpha-Hydroxylase*
  • Steroid Hydroxylases / metabolism

Substances

  • Cytochrome P-450 Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyridines
  • Cyclosporine
  • Cytochrome P-450 Enzyme System
  • cerivastatin
  • Mixed Function Oxygenases
  • Steroid Hydroxylases
  • Aryl Hydrocarbon Hydroxylases
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A
  • Steroid 16-alpha-Hydroxylase
  • Pravastatin